Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Foundation Grant

University of British Columbia

$1,160,050.00

When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events

EF 2015-16

Résumé
Medications have transformed the lives of Canadians who suffer from painful or debilitating illnesses. However, medications may also cause harm. As medication use rises, so does the incidence of adverse drug events-harmful and unintended events related to medication use. Today, adverse drug events cause 1.7M annual emergency department visits in Canada, and are a leading cause of hospital admissions. Identifying and treating patients with adverse drug events is not easy. Healthcare providers often unknowingly re-expose patients to medications that previously caused harm. This is because we misdiagnose 40% of adverse drug events, and lack effective ways of communicating information about these events between care providers even after the diagnosis is made. For example: "I saw a diabetic who was discharged from hospital recently, where he was admitted for hypoglycemia [low blood sugar] due to glyburide [a blood sugar lowering drug]. The physician asked him to stop the glyburide, and gave him a prescription for gliclazide, a drug with a lower risk of causing hypoglycemia. But the patient presented here comatose with an even lower blood sugar. When I looked at the patient's blister pack I discovered that both glyburide and gliclazide had been dispensed. The patient had been given a discharge prescription for gliclazide, but no note was made to discontinue glyburide, and neither the GP [general practitioner] nor the community pharmacist were aware of what had happened." Hospital pharmacist, 2012. To address this gap, I aim to develop, evaluate and implement innovative solutions to help healthcare providers diagnose and treat patients with adverse drug events, and prevent harmful re-exposure. My team plans to create the first adverse drug event surveillance program in Canada, improve the quality of data on adverse drug event outcomes, and create a new resource for health professionals to study safer prescribing, optimize medication use and improve health outcomes.
Programme
Foundation Grant
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
334184
Name
Hohl Corinne M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Foundation Grant - New Investigator
Projecttitle
When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$1,160,050
Cihrequipment2
$0
Programname2
Foundation Grant
Keyworddelim
Adverse Drug Events; Clinical Decision Rule; Drug Safety And Effectiveness; Emergency Medicine; Internal Medicine; Patient Safety; Surveillance
Abstract
Medications have transformed the lives of Canadians who suffer from painful or debilitating illnesses. However, medications may also cause harm. As medication use rises, so does the incidence of adverse drug events-harmful and unintended events related to medication use. Today, adverse drug events cause 1.7M annual emergency department visits in Canada, and are a leading cause of hospital admissions. Identifying and treating patients with adverse drug events is not easy. Healthcare providers often unknowingly re-expose patients to medications that previously caused harm. This is because we misdiagnose 40% of adverse drug events, and lack effective ways of communicating information about these events between care providers even after the diagnosis is made. For example: "I saw a diabetic who was discharged from hospital recently, where he was admitted for hypoglycemia [low blood sugar] due to glyburide [a blood sugar lowering drug]. The physician asked him to stop the glyburide, and gave him a prescription for gliclazide, a drug with a lower risk of causing hypoglycemia. But the patient presented here comatose with an even lower blood sugar. When I looked at the patient's blister pack I discovered that both glyburide and gliclazide had been dispensed. The patient had been given a discharge prescription for gliclazide, but no note was made to discontinue glyburide, and neither the GP [general practitioner] nor the community pharmacist were aware of what had happened." Hospital pharmacist, 2012. To address this gap, I aim to develop, evaluate and implement innovative solutions to help healthcare providers diagnose and treat patients with adverse drug events, and prevent harmful re-exposure. My team plans to create the first adverse drug event surveillance program in Canada, improve the quality of data on adverse drug event outcomes, and create a new resource for health professionals to study safer prescribing, optimize medication use and improve health outcomes.
Competitiondate
201509
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Hohl, Corinne M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,160,050~ $0~